UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice.

CONCLUSION: Aflibercept achieved greater VA gains at 1 year than ranibizumab. The observed VA differences are small and likely to be related to more frequent treatment with aflibercept, suggesting that ranibizumab should also be delivered by F/TE posology.
PMID: 28478396 [PubMed - as supplied by publisher]

Source: The British Journal of Ophthalmology - May 6, 2017 Category: Opthalmology Authors: Lee AY, Lee CS, Egan CA, Bailey C, Johnston RL, Natha S, Hamilton R, Khan R, Al-Husainy S, Brand C, Akerele T, Mckibbin M, Downey L, Tufail A Tags: Br J Ophthalmol Source Type: research